Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
| dc.rights.license | open | en_US |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | CANET, Jim | |
| dc.contributor.author | CONY-MAKHOUL, Pascale | |
| dc.contributor.author | ORAZIO, Sebastien | |
| dc.contributor.author | CORNET, Edouard | |
| dc.contributor.author | TROUSSARD, Xavier | |
| dc.contributor.author | MAYNADIE, Marc | |
| dc.contributor.author | ETIENNE, Gabriel | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MONNEREAU, Alain | |
| dc.date.accessioned | 2021-11-22T13:18:25Z | |
| dc.date.available | 2021-11-22T13:18:25Z | |
| dc.date.issued | 2021-09-22 | |
| dc.identifier.issn | 2045-7634 (Electronic) 2045-7634 (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/123914 | |
| dc.description.abstractEn | INTRODUCTION: Since 2009, multiple randomized trials have shown faster and deeper responses in CML patients treated with new-generation TKI (NG-TKI) compared to those treated with imatinib (IM). Are the same results observed in the general population? MATERIALS AND METHODS: Patients were identified from the three French hematological malignancies population-based registries. All CML patients (ICD-O-3: 9875/3) diagnosed between 2006 and 2016 and resided in registries areas were included. The TKI generation effect on achievement of MMR in first-line therapy was assessed through a multivariate competitive risk analysis. An alluvial plot described the pathways leading to death. RESULTS: In total, 507 CML patients received TKI in first-line treatment, 22% were enrolled in a clinical trial. After adjustment, NG-TKI patients were significantly more likely to achieve MMR during first-line therapy than IM patients (HR: 1.88 CI95% [1.35-2.61]). At the end of follow-up, 212 patients were still in first-line therapy (46 of them died), 203 switched to second-line (43 subsequently died), 26 were on TFR from first-line (4 subsequently died), and 20 stopped their treatment (16 subsequently died). DISCUSSION: In this comprehensive real-life setting, the results were consistent with clinical trials. The results are not sufficient to conclude that a NG-TKI treatment is superior with regard to these patients, despite indications regarding differences between the TKI generation effect on survival and tolerance. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.subject.en | Chronic myeloid leukemia | |
| dc.subject.en | Observational study | |
| dc.subject.en | Population-based cancer registries | |
| dc.subject.en | Real life | |
| dc.subject.en | Tyrosine kinase inhibitor | |
| dc.title.en | Second- or third-generation tyrosine kinase inhibitors in first-line treatment of chronic myeloid leukemia in general population: Is there a real benefit? | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1002/cam4.4186 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 34551198 | en_US |
| bordeaux.journal | Cancer Medicine | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | EPICENE_BPH | |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03440252 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-11-22T13:18:29Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cancer%20Medicine&rft.date=2021-09-22&rft.eissn=2045-7634%20(Electronic)%202045-7634%20(Linking)&rft.issn=2045-7634%20(Electronic)%202045-7634%20(Linking)&rft.au=CANET,%20Jim&CONY-MAKHOUL,%20Pascale&ORAZIO,%20Sebastien&CORNET,%20Edouard&TROUSSARD,%20Xavier&rft.genre=article |
